Qing Yi

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Novel immunotherapies
    Qing Yi
    Division of Cancer Medicine, Department of Lymphoma and Myeloma, Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer J 15:502-10. 2009
  2. pmc Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients
    Qing Yi
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 150:554-64. 2010
  3. pmc Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma
    Jianfei Qian
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and Center for Cancer Immunology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 114:3880-9. 2009
  4. pmc Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts
    Jing Yang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and Center for Cancer Immunology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:3028-35. 2007
  5. pmc Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma
    Jianfei Qian
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:1587-94. 2007
  6. pmc Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells
    Haiyan Li
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 116:210-7. 2010
  7. pmc Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis
    Yuhuan Zheng
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 114:3625-8. 2009
  8. doi Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone
    Yuhuan Zheng
    Department of Lymphoma Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Mol Med (Berl) 90:695-706. 2012
  9. doi Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo
    Zhengzi Qian
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Leuk Res 35:380-6. 2011
  10. ncbi Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis
    Jing Yang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 12:252-65. 2007

Collaborators

Detail Information

Publications33

  1. pmc Novel immunotherapies
    Qing Yi
    Division of Cancer Medicine, Department of Lymphoma and Myeloma, Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer J 15:502-10. 2009
    ..Based on the specificity of the immune effector molecules and cells, immunotherapies with specific T cells or therapeutic antibodies may represent novel strategies for the treatment of multiple myeloma in the near future...
  2. pmc Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients
    Qing Yi
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 150:554-64. 2010
    ..Current efforts are geared towards breaking tumour-mediated immune suppression and improving clinical efficacy of this immunotherapy...
  3. pmc Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma
    Jianfei Qian
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and Center for Cancer Immunology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 114:3880-9. 2009
    ....
  4. pmc Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts
    Jing Yang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and Center for Cancer Immunology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:3028-35. 2007
    ..Thus, this study further defines the tumoricidal mechanism of the mAbs and provides strong evidence to support the potential of these mAbs as therapeutic agents for myeloma...
  5. pmc Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma
    Jianfei Qian
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:1587-94. 2007
    ..Hence, our study identifies DKK1 as a potentially important antigen for immunotherapy in MM...
  6. pmc Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells
    Haiyan Li
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 116:210-7. 2010
    ....
  7. pmc Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis
    Yuhuan Zheng
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 114:3625-8. 2009
    ..Thus, our results indicate that Mvarphis may contribute to myeloma cell survival and resistance to chemotherapeutic treatment in vivo...
  8. doi Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone
    Yuhuan Zheng
    Department of Lymphoma Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Mol Med (Berl) 90:695-706. 2012
    ..In summary, our findings demonstrate the in vitro and in vivo anti-MM activity of BKM120 and suggest that BKM120 alone or together with other MM chemotherapeutics, particularly dexamethasone, may be a promising treatment for MM...
  9. doi Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo
    Zhengzi Qian
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Leuk Res 35:380-6. 2011
    ..Importantly, the combination of LEN and DEX delayed the tumor growth and improved the survival of MCL-bearing mice. The results support the use of the LEN and DEX combination as a new therapeutic regimen in clinical trials of MCL...
  10. ncbi Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis
    Jing Yang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 12:252-65. 2007
    ..CRP also enhanced myeloma cell secretion of IL-6 and synergized with IL-6 to protect myeloma cells from chemotherapy drug-induced apoptosis. Thus, our results implicate CRP as a potential target for cancer treatment...
  11. doi A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma
    Michael Wang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:2154-60. 2008
    ..To establish a severe combined immunodeficient (SCID)-hu in vivo mouse model of human primary mantle cell lymphoma (MCL) for the study of the biology and novel therapy of human MCL...
  12. pmc p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction
    Jin He
    Department of Lymphoma Myeloma, Division of Cancer Medicine and Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 72:6393-402. 2012
    ....
  13. pmc CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma
    Sungyoul Hong
    Department of Lymphoma Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0903, Houston, TX 77030, USA
    Cancer Immunol Immunother 61:561-71. 2012
    ..Thus, our study clearly shows that CpG or IFN-α are better immune adjuvants than GM-CSF. This information will be important for improving the strategies of Id-based immunotherapy for patients with myeloma and other B-cell tumors...
  14. pmc Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma
    Jianfei Qian
    Department of Lymphoma Myeloma, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 119:161-9. 2012
    ..Thus, our studies provide strong rationale for targeting DKK1 for immunotherapy of myeloma patients...
  15. pmc Targeting cell surface β2 -microglobulin by pentameric IgM antibodies
    Yabing Cao
    Department of Lymphoma Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 154:111-21. 2011
    ..Thus, we developed and validated the efficacy of anti-β(2) M IgM mAbs that may be utilized in the clinical setting and showed that IgM anti-β(2) M mAbs may be more potent than IgG mAbs at inducing tumour apoptosis...
  16. pmc Th9 cells promote antitumor immune responses in vivo
    Yong Lu
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Invest 122:4160-71. 2012
    ..Our data suggest a distinct role for tumor-specific Th9 cells in provoking CD8+ CTL-mediated antitumor immunity and indicate that Th9 cell-based cancer immunotherapy may be a promising therapeutic approach...
  17. doi Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo
    Luhong Sun
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Res 36:363-8. 2012
    ..Our results demonstrate that ATI and BTZ confer significant therapeutic effects in MCL in vitro and in vivo and should therefore be investigated in a clinical trial in patients with relapsed or refractory MCL...
  18. ncbi Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma
    Siqing Wang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer, Houston, Texas 77030, USA
    Front Biosci 12:3566-75. 2007
    ..Further studies are needed to optimize methods of DC-based vaccines to improve the efficacy of clinical trials...
  19. pmc Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth
    Sungyoul Hong
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 68:8456-64. 2008
    ..These results show that Id-specific CTL and Th1 are promising effector cells, whereas Th2 provide no protection and may even promote tumor progression in vivo...
  20. doi Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion
    Lijuan Wang
    Department of Lymphoma Myeloma, Center for Cancer Immunology Research, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 119:782-91. 2013
    ..Because Toll-like receptors (TLRs) initiate innate and adaptive immune responses against invading pathogens, the authors investigated the impact of TLR signaling in MCL cells...
  21. pmc Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells
    Liang Zhang
    Department of Lymphoma Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 120:3783-92. 2012
    ..Hence, our study identifies IL-6 as a key cytokine for MCL growth and survival and suggests that targeting the IL-6 pathway may be a novel way to improve the efficacy of chemotherapy in MCL patients...
  22. pmc Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells
    Siqing Wang
    Department of Lymphoma and Myeloma, Center for Cancer Immunology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 108:4071-7. 2006
    ..Thus, this study has delineated the mechanistic defects of MoDCs from myeloma patients and identified ways for restoring the function of the cells to improve the efficacy of DC-based immunotherapy in this disease...
  23. ncbi Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies
    Jing Yang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Cell 10:295-307. 2006
    ..Therefore, such mAbs offer the potential for a therapeutic approach to hematological malignancies...
  24. doi Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo
    Liang Zhang
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Am J Hematol 84:553-9. 2009
    ....
  25. pmc Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma
    Jing Yang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:951-9. 2009
    ....
  26. pmc Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression
    Zhiqiang Liu
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 8:e82453. 2013
    ..Thus, our studies provide evidences that targeting bone marrow microenvironmental cells and/or cytokines may be a new approach to treating MM bone destruction. ..
  27. pmc Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules
    Jing Yang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 116:1638-45. 2010
    ..These findings suggest that targeting beta(2)M or MHC class I by using antibodies or other agents offers a potential therapeutic approach for beta(2)M/MHC class I-expressing malignancies. Cancer 2010. (c) 2010 American Cancer Society...
  28. pmc Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes
    Jinsheng Weng
    Department of Lymphoma and Myeloma, Stem Cell Transplantation and Cellular Therapy, and Center for Cancer Immunology Research, MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 17:5945-52. 2011
    ..However, epitopes derived from Id that stimulate human CD8(+) T-cell immunity are incompletely characterized...
  29. ncbi Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways
    Michael Wang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 109:5455-62. 2007
    ..Cell apoptosis was induced mainly via activation of the AIF pathway. These results support the use of atiprimod as a potential agent in MCL chemotherapy...
  30. pmc Effect of long-term storage in TRIzol on microarray-based gene expression profiling
    Wencai Ma
    The Myeloma Tissue and Leukemia Satellite Sample Banks, Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, Texas 77054, USA
    Cancer Epidemiol Biomarkers Prev 19:2445-52. 2010
    ....
  31. doi In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome
    Liang Zhang
    Corresponding Authors Liang Zhang, Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0903, Houston, TX 77030
    Mol Cancer Ther 12:2494-504. 2013
    ..Furthermore, an intact i-proteasome, especially LMP2, appears to be necessary for its anti-MCL activity, suggesting that i-proteasome could serve as a biomarker for identifying patients who will benefit from carfilzomib...
  32. doi Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004
    Yuhong Zhou
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:791-8. 2008
    ..The purpose of the current study was to examine the incidence of MCL over a period of 13 years and to identify the factors associated with the incidence patterns...
  33. pmc Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma
    Siqing Wang
    Department of Lymphoma and Myeloma, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:2432-9. 2006
    ....

Research Grants13

  1. Targeting surface b2M for myeloma and bone therapy
    Qing Yi; Fiscal Year: 2010
    ..abstract_text> ..
  2. Optimizing Dendritic Cell Immunotherapy in Myeloma
    Qing Yi; Fiscal Year: 2007
    ..These innovative approaches will substantially contribute to the ability of immunotherapy to induce or improve long-term survival in patients with MM. ..
  3. Idiotype-specific effector T cells in multiple myeloma
    Qing Yi; Fiscal Year: 2006
    ..These novel approaches will substantially contribute to the ability of immunotherapy to induce or improve long-term survival in patients with MM. ..
  4. C-reactive protein promotes myeloma cell-mediated bone destruction
    Qing Yi; Fiscal Year: 2010
    ....